Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). It can cause many symptoms related to low sodium or other electrolyte ...

For the first time in years, small cell lung cancer (SCLC) patients have reason for renewed hope. Exciting new research presented at the American Society of Clinical Oncology (ASCO) 2025 conference is ...

Small cell lung cancer (SCLC) often responds well to initial treatment before later relapsing. Researchers are continuing to investigate new treatments, such as targeted therapy and immunotherapy ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

Small cell lung cancer (SCLC) is among the most aggressive types of lung cancer, with a five-year survival rate of just five percent. Although it often responds well to chemotherapy at first, that ...

Purdue University scientists have identified the Supinoxin small-molecule drug as a possible new therapy for small-cell lung cancer (SCLC). "Some cancer types are incredibly difficult to treat, one of ...

LEMS is an autoimmune disorder linked to SCLC, causing muscle weakness and autonomic dysfunction due to presynaptic calcium channel antibodies. Differentiation from myasthenia gravis involves ...

FDA grants Fast Track designation to VS-7375, an oral investigational KRAS G12D inhibitor, for locally advanced or metastatic ...

A new study by Australia’s Walter and Eliza Hall Institute of Medical Research (WEHI) finds a new blood marker that might be ...